FREEMAN KEVIN D

Director Freeman bought 5,500 GALT shares at $3.55; stock down 38.7% from 52-week high, company unprofitable.

Director Kevin D Freeman purchased 5,500 shares at $3.55 on 2025-12-23, increasing his holdings by 11.1% to 55,269 shares. The buy occurs in an unfavorable price environment: the stock is currently $3.99, down 38.7% from its 52-week high of $6.51 and down 25.4% over the prior 30 days. Freeman's same-ticker history at GALT shows mixed predictive power, with 2 of 5 prior buys achieving positive 90-day returns, but the company posted a net loss of $8,184,000.00 in its most recent full fiscal year. The timing and valuation context do not clearly signal insider conviction about near-term recovery, particularly given recent downward price momentum and ongoing unprofitability.

Director Kevin Freeman bought 5,000 shares of GALT at $2.90; stock now at $2.80, down 14.9% in 30 days from purchase.

Freeman purchased 5,000 shares at $2.90 on 2025-07-17, increasing his holdings from 44.8K to 49.8K shares (+11.2%), for a total outlay of $14.5K. The stock has declined to $2.80 current price, representing a -14.9% loss from his purchase price in just over a month. Across his prior 5 trades in GALT, Freeman's timing outcomes were mixed: 2 of 5 buys achieved positive 90-day returns (well-timed), while 3 underperformed, with 90-day declines ranging from -51.5% to -57.4%. The company remains unprofitable with a net loss of $-9.6M over its most recent full fiscal year, and the stock is trading 14.9% below its 52-week high of $3.29.

Director Kevin D Freeman buys 10,000 GALT shares at $0.81; stock down -79.3% from 52-week high, company unprofitable.

Freeman, a director of Galectin Therapeutics, purchased 10,000 shares at $0.81 on 2024-12-24, increasing his holdings by 28.8% to 44.8K shares. The transaction occurred in a context of significant price deterioration: the stock is -79.3% from its 52-week high of $4.20 and has declined -68.6% over the prior 30 days. At the same ticker, Freeman has a mixed track record: 5 prior purchases show a 50% win rate at the 90-day mark, with outcomes ranging from +13.9% to -18.8%. The company is unprofitable, posting a net loss of $-11.2M over its most recent fiscal year. Notably, 2 other insiders also bought GALT within the past 14 days, suggesting alignment among multiple board/management members on valuation at current depressed levels.

Director Freeman buys 1,300 shares of GALT at $2.64; stock now $2.66, down 36.7% from 52-week high

KEVIN D FREEMAN purchased 1,300 shares at $2.64 on 2024-10-17, increasing his holdings to 34,769 shares (+3.9%). The transaction occurred in a context of price weakness: the stock is currently $2.66, representing a 36.7% decline from its 52-week high of $4.20 and down 4.0% over the prior 30 days. Freeman's same-ticker history at GALT shows mixed outcomes—one prior buy from June 2024 yielded a 90-day return of +13.9%, while an April 2024 buy produced a 90-day return of -18.8%, with a 50% timing success rate across measurable trades. The company is unprofitable with a net income of $-12,371,000.00 over its most recent full fiscal year, though the market cap of $165,659,812.50 remains substantial. The magnitude of this single purchase ($3,432.00) is modest relative to his aggregate holdings, and repeated purchases on consecutive days (2024-10-16) suggest incremental accumulation rather than a concentrated conviction signal.

Director Kevin D Freeman bought 10,000 shares of GALT at $2.70 (2 transactions) on 2024-10-16, raising holdings to 80,000 shares

Director Freeman executed 2 separate purchases totaling 10,000 shares for $27,000.00 at $2.70, increasing his position from 70,000 to 80,000 shares. The current price of $2.63 is slightly below his entry, and the stock is trading -37.4% from its 52-week high of $4.20. Freeman's prior trade at GALT on 2024-06-20 achieved a 90-day return of +13.9%, demonstrating successful timing on that occasion, while his April 2024 purchase returned -18.8% at the 90-day mark. The company is unprofitable with a net income of $-12.4M over its most recent full fiscal year, adding fundamental headwind to equity valuations. This accumulation occurs within a context of prior mixed execution and ongoing losses, making the director's willingness to add to his stake a data point worth monitoring against near-term price action and company financial recovery.

Director Kevin D Freeman purchased 2,500 shares of GALT at $2.38 on 2024-06-20; stock down 42.4% from 52-week high.

Kevin D Freeman, a Director, purchased 2,500 shares of Galectin Therapeutics (GALT) at $2.38, increasing his holdings from 26.0K shares to 28.5K shares. The purchase occurred as the stock was trading 42.4% below its 52-week high and has declined 25.1% over the prior 30 days, suggesting the insider was accumulating during a period of weakness. The company's fundamentals show a net loss of $-11.5M with an unprofitable fiscal year, and prior timing analysis of Freeman's cross-ticker track record shows limited evidence of strong execution—his single prior GALT trade on 2024-04-22 achieved a positive 30-day return of 4.4%, but insufficient history at this ticker precludes a reliable pattern assessment.